340B Spotlight

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients

The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the program. Today, we’re correcting the record. Fact: Manufacturers are still giving the 340B discounts, as required by law, to “covered entities” – more than 12,700 …

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients Read More »

340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients

The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are always helping needy patients. At a time when too many Americans struggle to access the medicines and care they need, it is alarming to …

340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients Read More »

Growth in 340B program has not translated to improvements for patients

Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That’s the most important question policymakers should be asking in any discussion about the 340B program. Unfortunately, this program is essentially a black box with lax reporting requirements and weak oversight – which means there is little to no clear evidence that patients …

Growth in 340B program has not translated to improvements for patients Read More »